Maximum Diameter of Intracranial Metastatic Lesions as a Prognostic Factor in Patients Following Whole Brain Radiotherapy
- PMID: 27509998
Maximum Diameter of Intracranial Metastatic Lesions as a Prognostic Factor in Patients Following Whole Brain Radiotherapy
Abstract
Purpose: To evaluate whetehr maximum diameter of intracranial metastatic lesions may be a prognostic factor in intracranial metastatic patients receiving whole brain radiotherapy.
Materials and methods: The records of 114 cases who between January 2005 and December 2007 were retrospectively reviewed. There were 85 who met the inclusion criteria.
Results: In these 85, the oneyear overall survival rate was 16.5% and the median survival time was 125 days. Median survival in relation to recursive partitioning analysis (RPA) classes I, II and III were 216, 133 and 85 days. Logrank tests of initial prognostic factors were significant for RPA classifications, Karnofsky Performance Status(KPS), maximum diameters of intracranial metastatic lesions and presence of necrotic centers. The median survivals with a maximum diameter of the largest intracranial metastatic lesion <3cm and ≥3cm were 162 days and 104 days (p=0.027). Multivariate analysis also showed a statistical significance for maximum diameter of intracranial metastatic lesions and presence of necrotic centers.
Conclusions: Maximum diameters of intracranial metastatic lesions could be used as a prognostic factor in patients receiving whole brain radiotherapy and may help radiation oncologists to make decisions on treatment plans.
Similar articles
-
Prognostic effect of symptomatic extracranial lesions on survival of recursive partitioning analysis Class III brain metastatic patients treated with stereotactic radiotherapy.J Cancer Res Ther. 2016 Jan-Mar;12(1):215-20. doi: 10.4103/0973-1482.160925. J Cancer Res Ther. 2016. PMID: 27072240
-
Recursive partitioning analysis (RPA) class does not predict survival in patients with four or more brain metastases.Strahlenther Onkol. 2003 Jan;179(1):16-20. doi: 10.1007/s00066-003-1028-x. Strahlenther Onkol. 2003. PMID: 12540980
-
Brain metastases from breast carcinoma: validation of the radiation therapy oncology group recursive partitioning analysis classification and proposition of a new prognostic score.Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):839-45. doi: 10.1016/j.ijrobp.2007.04.024. Epub 2007 Jun 4. Int J Radiat Oncol Biol Phys. 2007. PMID: 17544592
-
Institutional, retrospective analysis of 777 patients with brain metastases: treatment outcomes and diagnosis-specific prognostic factors.Int J Radiat Oncol Biol Phys. 2013 Jul 15;86(4):630-7. doi: 10.1016/j.ijrobp.2013.02.027. Epub 2013 Apr 11. Int J Radiat Oncol Biol Phys. 2013. PMID: 23582409
-
Whole-brain radiotherapy with 20 Gy in 5 fractions for brain metastases in patients with cancer of unknown primary (CUP).Strahlenther Onkol. 2007 Nov;183(11):631-6. doi: 10.1007/s00066-007-1763-5. Strahlenther Onkol. 2007. PMID: 17960339
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous